Moderna stock steadies as RSV and COVID vaccine revenues reshape outlook

Moderna Inc. (ISIN US60770K1034) stock is trading in a market that is recalibrating the companys valuation around post-pandemic vaccine demand, with investors now focused on 2024 revenue guidance and the first full commercial year for its respiratory syncytial virus, or RSV, vaccine. As of early 2024 trading data from major US exchanges, Moderna carried a multibillion-dollar market capitalization, down significantly from its peak when COVID-19 vaccine sales exceeded $18 billion in 2021, highlighting how the end of the acute pandemic has reshaped expectations for the Nasdaq-listed biotechnology group.

Revenue falls from 2022 peak

According to figures Moderna has reported for recent fiscal years, total revenue in 2022 reached roughly $19 billion, driven primarily by global COVID-19 vaccine contracts with governments and large purchasers. In 2023, however, annual revenue dropped to around $6 billion as many of those large advance-purchase agreements rolled off and demand shifted toward seasonal booster campaigns, marking a decline of roughly two-thirds compared with the prior year.

Moderna has communicated that for 2024 it expects revenue in a range of about $4 billion, reflecting a further step down from 2023 but also a stabilization compared with the sharp decline from 2022 to 2023. This outlook is built largely on anticipated sales of its updated COVID-19 vaccines, combined with the ramp-up of its newly approved RSV product in key markets such as the United States and Europe. The guidance illustrates how the company is attempting to transition from a one-off pandemic revenue spike to a recurring seasonal respiratory franchise.

RSV launch and respiratory franchise above $4 billion

The RSV program is central to that transition. Modernas RSV vaccine has been authorized for use in older adults, opening a commercial opportunity in a market that already includes established competitors targeting the same virus. The company has indicated that, over the medium term, it is targeting more than $4 billion in annual respiratory vaccine revenue across COVID-19, RSV, and influenza, though near-term sales will depend on uptake in the critical first seasons for each product.

COVID-19 vaccine revenue itself has shifted from bulk government procurement to distribution through pharmacy and healthcare channels, particularly in the United States. While annual global sales in 2021 reached well above $18 billion for Moderna, the company now expects COVID-related revenue alone to be markedly lower but more stable, in line with an endemic pattern where many individuals receive a seasonal booster, similar to influenza vaccination campaigns.

Pipeline investment weighs on profit

As the revenue base has normalized, Moderna has continued to invest heavily in its research and development pipeline, particularly in oncology, rare disease, and additional vaccine candidates based on its messenger RNA technology. In its recent annual reporting, the company disclosed R&D expenses in the multibillion-dollar range for 2023, compared with significantly lower levels before the pandemic windfall enabled it to expand programs rapidly.

These elevated R&D and commercialization costs, combined with lower COVID-19 vaccine revenue, have led to a swing from the high profitability of 2021 and 2022 to losses in later periods. Net income in 2021 reached several billion dollars on the back of those exceptional vaccine sales, while in 2023 Moderna reported a net loss as operating expenses outpaced the reduced top line. For investors analyzing Moderna stock today, the key question is how quickly new products can offset the decline in legacy COVID-19 revenue and move the company back toward sustainable profitability.

mRNA COVID-19 vaccine remains flagship product

Modernas flagship product is its mRNA-based COVID-19 vaccine, which was among the first such vaccines authorized globally and has been updated periodically to match circulating variants. The shot demonstrated strong efficacy in pivotal trials during the acute phase of the pandemic, which underpinned the large-scale supply agreements with governments that drove 2021 and 2022 revenue.

Beyond COVID-19, the company is advancing a portfolio that includes combination respiratory vaccines that could cover COVID-19 and influenza in a single shot, as well as experimental cancer vaccines and therapies for rare genetic conditions. The long-term bull case for Moderna stock hinges on whether at least some of these candidates can reach the market and generate material revenue, diversifying the company away from a single-product dependence.

Moderna stock in the market context

Moderna shares trade on the Nasdaq in US dollars and are part of a broader cohort of biotechnology companies that saw significant valuation swings through the pandemic period. From 2021 peaks, the stock has experienced a pronounced decline in line with the normalization of COVID-19 vaccine demand and the broader recalibration of biotech valuations after a period of intense enthusiasm for vaccine and therapeutic developers.

Even at a lower share price than during the pandemic highs, Moderna remains a sizeable component of the US biotechnology universe, with a market capitalization in the tens of billions of dollars based on recent trading data. For investors, the shift in narrative from one-off pandemic windfalls to a diversified mRNA platform means that valuation is increasingly tied to execution on RSV, influenza, and oncology programs rather than to emergency-use vaccine orders.